Summary
Summary

A retrospective study was carried out in the Ferrara Local
Barré syndrome was higher in the exposed (0.53 (nine patients, 20.9%), and, secondly, to verify groups differed in age (those exposed were older than those the sequence of events between the ganglioside injection and unexposed and the age-specific incidence of Guillain-Barré the onset of the disease. Seven of the nine patients (77.8%) syndrome
in the study population increased with increasing received gangliosides as treatment for peripheral neuropathy age), the present findings question either a strong increased (Guillain-Barré syndrome onset before gangliosides were risk of Guillain-Barré syndrome in people exposed to prescribed). For the other two patients (22.2%) a possible exogenous gangliosides or an immunogenic role of these appropriate temporal sequence between ganglioside injection agents in humans. However, because of the limited sample and onset of Guillain-Barré syndrome was found. Based on
Introduction
Between 20% and 30% of patients with Guillain-Barré and Garattini, 1993; Keates, 1994) . The prescription data syndrome have high titres of serum anti-ganglioside antiwere collected in the Local Health Districts (the local agencies bodies, most frequently against GM1 and GD1b (Ilyas et al., of the Italian National Health Service) data banks for financial 1992; van den Berg et al., 1992) . The pathogenetic relevance purposes. Since the Local Health Districts data banks of anti-ganglioside antibodies in Guillain-Barré syndrome collected only prescriptions of drugs issued by public has not yet been established (Kusunoki et al., 1996) . It is physicians under contract by the Italian National Health controversial as to whether these antibodies are markers of Service, ganglioside prescriptions for private patients could a poor prognosis due to axonal degeneration and whether have been missed. However, as the Italian National Health they are associated with Campylobacter jejuni infection (Rees Service dispensed gangliosides free of charge through the et al., 1995). Gangliosides extracted from bovine brain were Local Health Districts the list of ganglioside prescriptions extensively prescribed in Italy, mainly for the treatment of of the Local Health Districts represented virtually 100% of peripheral neuropathies, after their introduction in 1975 ganglioside sales in the corresponding geographical area. In (Garattini and Garattini, 1993) . A neuroprotective role and fact, it is unlikely that a patient paid for these fairly expensive their potential to promote nerve repair by enhancing nerve drugs when he could get them free through the Local Health sprouting was asserted (Roisen et al., 1981; Ledeen, 1984) .
District. Moreover, since Italian citizens are entitled to the Cases of Guillain-Barré syndrome after ganglioside injection drugs dispensed free of charge by the Italian National Health have been reported (Schönhöfer, 1991; Figueras et al., 1992;  Service it was normal practice when a private physician Landi et al., 1993) . High titres of anti-GM1 or asialo-GM1 advised a patient to take such a drug that the prescription was antibodies were found in some of them (Latov et al., 1991;  then issued by a general practitioner. Five drugs containing Nobile-Orazio et al., 1992) . A causal association between gangliosides were available on the Italian market: three were ganglioside injection and Guillain-Barré syndrome was a fixed mixture of bovine brain gangliosides (GM1 21%, inferred (Behan and Haniffah, 1992) and gangliosides were GD1a 40%, GD1b 16%, GT1b 19%), one was a mixture of withdrawn in Italy in December 1993 (Keates, 1994 .
the ethers of these four main gangliosides of bovine brain, Although gangliosides are thought to be immunogenic, the and the other one contained only GM1. mechanism of ganglioside-induced Guillain-Barré syndrome
We submitted the research plan of the present study to has not yet been established. Moreover, because anti-GM1 the Chief Executive and the Management of Ferrara Local antibodies can be non specific, their pathogenetic role in Health District. The research plan was approved and access Guillain-Barré syndrome has been questioned (Weller et al., to Ferrara Local Health District data bank was authorized. 1992; Mizutamari et al., 1994) . Guillain-Barré syndrome
The Electronic Data Processing Centre of Ferrara Local following exogenous gangliosides offers an opportunity to Health District supplied us with the data on ganglioside investigate their causal relationship in triggering Guillainprescriptions in Ferrara Local Health District resident Barré syndrome, the immunogenic role of these agents population so that the number of exposed individuals could in humans, and the pathogenetic role of antiganglioside be estimated. The computerized data base of Ferrara Local antibodies. It would be important to establish whether Health District supplies the name of the proprietary medical individuals exposed to exogenous gangliosides have a higher product, the type of package, the number of packages sold, risk of Guillain-Barré syndrome. However, owing to the the date of drug prescription, the date of drug sale, the name unknown size of exposed populations, reports on Guillainand the Italian National Health Service identification code of Barré syndrome after gangliosides do not include estimates the patient (which being unique for each resident of Ferrara of Guillain-Barré syndrome risk in exposed people. One Local Health District makes it possible to know the patient's Guillain-Barré syndrome case after gangliosides was reported personal data), the name and identification code of the in 1992 in the Local Health District of Ferrara, Italy (Landi physician. The data available made a drug utilization study et al., 1993) . For this reason, a study has been carried out in possible for the 4-year period 1988-1991. The Italian National Ferrara Local Health District to estimate the risk of GuillainHealth Service identification code allowed us to exclude the Barré syndrome in people exposed to gangliosides.
prescriptions issued by physicians working in Ferrara Local Health District for non resident individuals. The incidence of Guillain-Barré syndrome in Ferrara Local Health District resident population in the years 1981-
Material and methods
1993 (average population: 177 235 inhabitants) was recently All Italian citizens are assisted by the Italian National Health estimated (Govoni et al., 1996) using the diagnostic criteria Service. Prescriptions of drugs included in the National of the National Institute of Neurological and Communicative Drug Formulary issued either by general practitioners or by Disorders and Stroke (Asbury et al., 1978) . The average rate specialists are routinely collected and processed for pharmacy (based on 43 cases) of 1.9/100 000 population/year, with reimbursement. The Italian National Health Service supplied 95% CI (confidence interval) of 1.3-2.5, was similar to that all prescriptions of gangliosides after their introduction in 1975 up to their withdrawal in late December 1993 (Garattini of other community-based studies (Alter, 1990) . Neither After the research plan was approved by the Chief Executive and the Management of Ferrara Local Health *GM1 21%, GD1a 40%, GD1b 16%, GT1b 19%.
District, the Electronic Data Processing Centre of Ferrara Local Health District was also authorized to provide us with prescriptions per 1000 population), and 49 246 packages (283.9 packages per 1000 population) ( Table 2 ). Based on the data on drug prescriptions received by the Guillain-Barré syndrome cases in Ferrara Local Health District resident the available data, we assumed that the proportion of Ferrara Local Health District resident population exposed to population during the 3 months (90 days) before their hospital admission for Guillain-Barré syndrome. Moreover, we were gangliosides in the study period 1981-1993 (average resident population: 177 235 inhabitants) was 3.7% and the number authorized to review the clinical files of the cases to obtain anamnestic data. The data were examined only by the authors of ganglioside prescriptions was 162.2 per 1000 population. Therefore, we assumed that 85 254 individuals of Ferrara (each of them is qualified as a specialist in neurology). For each patient the data were assessed using the following Local Health District resident population were exposed to gangliosides in the years 1981-1993 receiving 373 724 criteria: (i) an appropriate temporal sequence between drug administration and onset of neurological symptoms; (ii) ganglioside prescriptions (an average of 4.4 prescriptions for each individual). A 30-day period (~1 month, i.e. 1/12 presence of other potential aetiological factors or prior illnesses.
of 1 year) of presumed increased Guillain-Barré syndrome risk following each ganglioside prescription was considered The incidence of Guillain-Barré syndrome in Ferrara Local Health District resident population in the years [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] in agreement with the recommendations for antecedent events in Guillain-Barré syndrome (Larsen et al., 1985; Arnason (Govoni et al., 1996) was used as a reference for comparison. The test of significance for the comparison of the observed and Soliven, 1993). In fact, the hypothesis tested was an immunological reaction to the drug, and immunological and expected number of cases was based on the Poisson distribution. Based on Ferrara Local Health District data we responses usually manifest within one month of an etiological exposure (Larsen et al., 1985) . compared the incidence of Guillain-Barré syndrome in the group of individuals exposed to gangliosides and in the group
The data of the Ferrara Local Health District data bank showed that four of the 43 cases of Guillain-Barré syndrome of unexposed individuals of Ferrara Local Health District resident population. A retrospective study over the years (9.3%) were prescribed gangliosides within the 3-month period before hospital admission for Guillain-Barré considered for the estimate of the Guillain-Barré syndrome incidence (Govoni et al., 1996) , that is from January 1, 1981 syndrome. In a review of clinical files, no other patient with Guillain-Barré syndrome was found to have been treated to December 31, 1993 (when gangliosides were withdrawn), was performed. The 95% CI of incidence rates was computed with gangliosides before hospital admission. Two of these four patients were prescribed gangliosides by their family assuming a Poisson distribution (Schoenberg, 1983) . The log-likelihood ratio test was used to compare two rates.
doctor, clearly after the onset of Guillain-Barré syndrome. The gangliosides were administered as treatment for early The actual difference and the 95% CI associated with the difference in rates were calculated using the Poisson symptoms and signs of peripheral neuropathy due to GuillainBarré syndrome in the days immediately preceding admission distribution (Rothman, 1986 ). The relative risk, i.e. the ratio of the incidence rate in the exposed group to the incidence to hospital. The available data showed that Guillain-Barré syndrome had begun 7 and 5 days before gangliosides were rate in the unexposed group, and the 95% CI associated with the relative risk were also estimated. The χ 2 test for linear administered to these two patients. Since an appropriate temporal sequence between ganglioside administration and trend was used when appropriate (Armitage, 1955) . onset of neurological symptoms was lacking we did not consider the relationship between gangliosides and GuillainBarré syndrome to be causal for these two patients. However,
Results
The number of individuals in the Ferrara Local Health District for the other two patients there was possibly an appropriate temporal sequence between ganglioside injection and onset resident population treated with gangliosides in the years 1988-1991 was 25 422, the prescriptions of gangliosides of Guillain-Barré syndrome. One patient had a 'flu-like' upper respiratory infection with fever for 4 days. (Landi et al., 1993) . The prescriptions (136.4 prescriptions per 1000 population) ( Table  2 ). Based on these data, 71 426 individuals of Ferrara Local other patient was treated with a fixed mixture of gangliosides and other drugs by the family doctor who suspected otitis
Health District resident population were exposed to mixed gangliosides in the years 1981-1993 receiving 314 275 (the subject complained of earache and tinnitus). After 8 days of treatment the patient developed Guillain-Barré prescriptions. Given the incidence of Guillain-Barré syndrome in Ferrara Local Health District resident population syndrome. We selected these two patients as possible cases of causal association between gangliosides and Guillainthe expected number of Guillain-Barré syndrome cases in the group exposed to mixed gangliosides was 0.5 (Poisson Barré syndrome in Ferrara Local Health District resident population in the years 1981-1993. The clinical files reported P value for exactly two cases ϭ 0.076; Poisson P value for two or fewer cases ϭ 0.986). The incidence of Guillain-Barré that five other cases of Guillain-Barré syndrome (11.6%) who never had treatment with gangliosides, received gangliosides syndrome was higher in exposed (0.64/100 000 population/ month following mixed ganglioside injection; 95% CI: during hospitalization for Guillain-Barré syndrome (gangliosides were prescribed by the neurologist only after 0.08-2.31) compared with unexposed people (0.15/100 000 population/month; 95% CI: 0.11-0.20), but the difference the diagnosis of Guillain-Barré syndrome).
Given the incidence of Guillain-Barré syndrome in the between the rates (actual difference ϭ 0.49; 95% CI: -0.40 and 1.38) was not statistically significant (G ϭ 2.64, 0.10 Ͻ Ferrara Local Health District resident population (1.9/100 000 population/year), the expected number of Guillain-Barré P Ͻ 0.20). However, the relative risk was borderline (relative risk ϭ 4.3; 95% CI: 1.0-17.8). syndrome cases in the group of individuals exposed to gangliosides (85 254 individuals exposed to gangliosides 373 724 times) was 0.6 (Poisson P value for exactly two cases 0.099; Poisson P value for two or fewer cases 0.977).
Discussion
The present findings confirm that gangliosides were widely As two individuals of the exposed group had a possible ganglioside-related Guillain-Barré syndrome, the incidence prescribed in Italy (Montanaro et al., 1992; Raschetti et al., 1992) . Almost all individuals treated in the Ferrara of Guillain-Barré syndrome in that exposed group was 0.53/ 100 000 population/month following ganglioside injection Local Health District resident population were prescribed gangliosides more than once and most of them several times. (95% CI: 0.06-1.91). The other 41 cases did not experience Guillain-Barré syndrome after ganglioside injection so that This was probably a result of the indications for gangliosides (peripheral neuropathies) which are mainly chronic the incidence of Guillain-Barré syndrome in the unexposed group was 0.15/100 000 population/month (95% CI: 0.11-disorders that often have no efficacious treatment. However, gangliosides were probably also prescribed for 0.20). The incidence was higher in exposed compared with unexposed individuals, but the difference between the rates other reasons outside the sphere of the approved indications and were suspected as being used as coadjuvants or placebos (actual difference ϭ 0.38; 95% CI: Ϫ0.36 and 1.12) was not statistically significant (G ϭ 2.22, 0.10 Ͻ P Ͻ 0.20). The (Montanaro et al., 1992; Garattini and Garattini, 1993) . In the present study 20.9% of Guillain-Barré syndrome cases relative risk was 3.5 (95% CI: 0.8-14.5).
Both the possible ganglioside-related cases received a received gangliosides. Most of them (55.5%) began ganglioside treatment in hospital only after the diagnosis of fixed mixture of gangliosides that were the most frequently prescribed ganglioside drug in the Ferrara Local Health Guillain-Barré syndrome had been confirmed by a neurologist, indicating that gangliosides were often used in District resident population (85.9% of all exposed individuals, 84.1% of all ganglioside prescriptions). The risk of GuillainItaly for the treatment of Guillain-Barré syndrome. Two of the four patients who received gangliosides before hospital Barré syndrome in the group exposed to mixed gangliosides was estimated. The number of individuals in the Ferrara admission showed a temporal sequence between drug injection and onset of neurological symptoms appropriate Local Health District resident population who were prescribed to there being a causal relationship with Guillain-Barré possible to estimate the proportion of Ferrara Local Health District resident population exposed to gangliosides, the syndrome. One of them has already been reported (Landi et al., 1993) . The other case was found thanks to the Ferrara number of cases of Guillain-Barré syndrome who had treatment with gangliosides, and to verify the sequence of Local Health District data bank. We considered these two patients as cases of possible causal relationships between events between the onset of symptoms and ganglioside injection. The non-concurrent prospective design of the study gangliosides and Guillain-Barré syndrome, but with reservation. The first patient had an optic neuritis that was seemed to be reliable as the geographic mobility of people into and out of Ferrara Local Health District is low (Govoni treated with gangliosides. No serum antibodies against GM1 were found with ELISA (enzyme linked immunosorbent et al., 1996) . Moreover, there was no problem in tracing individuals. A higher risk of Guillain-Barré syndrome in assay), and the patient recovered with no residual neurological deficit. However, since optic neuritis can be a feature of ganglioside-exposed than unexposed people was estimated, especially when mixed gangliosides were considered. Guillain-Barré syndrome (Pall and Williams, 1987; Nadkarni and Lisak, 1993 ) and a common antecedent event for However, the difference was not statistically significant, perhaps due to limitations in sample size. In fact, incidence Guillain-Barré syndrome before the visual loss is an upper respiratory infection with fever (sufferered by this patient), rates in exposed people had a wide 95% CI. The relative risk was borderline for mixed gangliosides. However, exposed it is not conclusive that the Guillain-Barré syndrome was attributable to gangliosides in this case. The other possible and unexposed people differed in age (Table 3) . Exposed people in Ferrara Local Health District resident population case was a patient who took other drugs (analgesic/antiinflammatory and antibiotic drugs) in addition to gangliosides, were older than unexposed people (94.7% of exposed people were Ͼ30 years of age compared with only 65.8% in and in this case another illness (otitis) preceded ganglioside administration. Raised serum anti-GM1 antibodies were unexposed people). This was predictable since the main indications for administration of gangliosides were peripheral found (ELISA). The patient had a moderate residual neurological deficit (able to walk). Since both cases had a neuropathies or radiculopathies that are for the most part disorders of adult or advanced age. In fact, the proportion of potential aetiological factor (an antecedent inflammatory illness) that preceded ganglioside injection, it would seem to exposed individuals by age-group increased with increasing age (χ 2 test for linear trend P Ͻ 0.0005). Also age-specific be a hasty deduction to consider that these two GuillainBarré syndrome cases were due to gangliosides. We adopted incidence of Guillain-Barré syndrome in Ferrara Local Health District resident population increased with increasing age (χ 2 a cautious attitude and estimated the probability of having two cases in our set of ganglioside-exposed people. Antecedent test for linear trend P Ͻ 0.0005) (Govoni et al., 1996) . As exposed and unexposed people differed in age, a factor which infections by various agents are reportedly associated with Guillain-Barré syndrome, but how infection triggers the is known to affect the risk of Guillain-Barré syndrome, it is likely that the higher incidence in exposed people was, at disease is unknown. It is therefore difficult to support a lack of a causal relationship between gangliosides and Guillainleast, partially due to the different age distribution. However, because of the limited sample size conclusive results cannot Barré syndrome in some cases, solely on the basis of an antecedent of the common cold, flu, or diarrhoea several be achieved. The possible relationship between gangliosides and days before the onset of symptoms. These two patients were regarded as only possible, not probable, ganglioside-related Guillain-Barré syndrome is an intriguing subject. Gangliosides have been implicated as major autoantigens in the cases since there was not sufficient evidence to prove or disprove a causal association, and a reasonable doubt as to immunopathological reaction of Guillain-Barré syndrome Illa et al., 1995) . No difference in the existence of this relationship still remains. It is difficult to assess a possible causal relationship when the available Guillain-Barré syndrome incidence has been reported between areas where use of gangliosides is either low or data made the sequence of events between the onset of symptoms and use of the drug unclear (Garcia et al., 1993) .
non-existent compared with those areas in which they are widely used, suggesting that large variations in ganglioside Prodromal and early symptoms of Guillain-Barré syndrome may be mild and difficult to define, and it is not always easy use do not influence Guillain-Barré syndrome incidence (Matias-Guiu et al., 1993) . A previous epidemiological to establish whether the drug was administered before the onset of neurological disturbances or whether it was study in the area of Ferrara failed to demonstrate an association between exogenous gangliosides and Guillainprescribed to treat early symptoms. Several of the reported ganglioside-related Guillain-Barré syndrome cases have been Barré syndrome, but the sample was too small to achieve conclusive results (Granieri et al., 1991) . The present study, questioned, as no definite causal relationship could be established after a review of available data (Diez-Tejedor however, did show evidence of a higher risk (although not of statistical significance) of Guillain-Barré syndrome in et al., 1993) . Further, a co-incidental association of GuillainBarré syndrome with ganglioside injection cannot be excluded exposed people. Immunological studies of comparative groups are essential considering the widespread use of gangliosides, at least in Italy.
to clarify the role of gangliosides in Guillain-Barré syndrome. Antibodies against GM1, asialo-GM1, GD1b, and GM2 The Ferrara Local Health District data bank made it can be detected in healthy individuals never treated with specificity for motor nerve terminals have recently been demonstrated in cases of acute motor axonal Guillaingangliosides (Mizutamari et al., 1994) , and anti-GM1, asialo-GM1, GD1a, and GD1b antibodies have been reported Barré syndrome after administration of mixed gangliosides, suggesting that exogenous gangliosides could serve as in other human neurological degenerative, infective, and inflammatory disorders as well as other peripheral neuroimmunogens against axonal targets and trigger an axonal form of Guillain-Barré syndrome (Illa et al., 1995) . The pathies such as diabetic neuropathy (Weller et al., 1992) . Anti-ganglioside antibodies could not cause nerve damage reported association of a high IgG GM1 antibody titre in patients with the acute axonal neuropathy due to Chinese in Guillain-Barré syndrome, but might occur in response to axonal injury (Ponzin et al., 1991) . Moreover, no correlation paralytic syndrome is consistent with these data (Kornberg et al., 1994) . Mixed gangliosides, which contain only 17-between anti-ganglioside antibody titres and clinical or histological involvement of the peripheral nerve has been found 25% GM1, might be more immunogenic than pure GM1 (Schneider and Roeltgen, 1993) . Patients receiving long term . However, the serum from one patient with anti-GM1 antibodies induced conduction block follow-GM1 for either stroke or acute spinal cord injury showed a lack of immune response to pure GM1 (Yu et al., 1992) . ing intraneural injection (Santoro et al., 1992) , and an increase in anti-GM1 and anti-GD1a antibodies in Guillain-Barré Both the two possible ganglioside-related cases in the present study were found in the group exposed to mixed gangliosides. syndrome may have a negative prognostic value (Simone et al., 1993) . High titres of anti-GM1 and anti-GD1a antiHowever, if an increased risk of Guillain-Barré syndrome in people exposed to mixed gangliosides does exist it seems to bodies have been found in patients with severe GuillainBarré syndrome, especially the predominantly motor axonal be low and not statistically higher than that in the general population of the Ferrara Local Health District. form characterized by axonal degeneration and poor prognosis (Nobile-Carpo et al., 1992; van den Berg et al., 1992; At present, Guillain-Barré syndrome is not considered to be a single entity and more than one underlying pathogenic et al., 1992; Gregson et al., 1993) . Cases of Guillain-Barré syndrome following ganglioside injection have been severe mechanism might be involved (Thomas, 1992) . In fact, similar clinical and spinal-fluid patterns can be seen in acute axonal polyneuropathies (Latov et al., 1991; Yuki et al., 1991; Illa et al., 1995) , and anti-ganglioside antibodies are individuals with quite different electrophysiology and pathology (Griffin et al., 1996) . Exogenous gangliosides could more common in axonal Guillain-Barré syndrome (Gregson et al., 1993) . Campylobacter jejuni, which bears crossbe immunogenic only in certain individuals, triggering certain forms of Guillain-Barré syndrome, such as the axonal form. reactivity with GM1, has been associated with GuillainBarré syndrome, lending support to the potential role of GM1 However, it is still unclear why Guillain-Barré syndrome develops in only a small fraction of ganglioside-injected as a factor in triggering autoimmune neuropathies (Enders et al., 1993) . GM1-reactive epitopes have been identified in patients. Concomitant muscle injury that exposes presynaptic epitopes, and host susceptibility, might be contributing factors the lipopolysaccharides of patients with axonal GuillainBarré syndrome (Griffin et al., 1996) . Furthermore, there is (Illa et al., 1995) . As an immune response to gangliosides may be found in normal individuals, the possibility cannot a close association between anti-GQ1b antibodies and Miller Fisher syndrome (Willison et al., 1993) as well as Guillainbe excluded that in some sensitized subjects exposure to gangliosides may occasionally trigger an antibody response Barré syndrome with ophthalmoplegia (Chiba et al., 1993) , and many GQ1b antibody-positive sera from Miller Fisher to gangliosides (Pestronk et al., 1990; Sadik et al., 1990) . However, whether this may occasionally lead to an acute syndrome patients cross-react with GD1b and GT1b (Dalakas and Quarles, 1996) . motor polyneuropathy, presenting as Guillain-Barré syndrome, remains unclear. Based on the present findings High antibody titre against GM1, asialo-GM1, GD1b, GD1a, GT1b, and IgG anti-ganglioside antibodies with this would be a rare event. In fact, the risk of Guillain-Barré 
